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Abstract
Background: Cardiovascular disease is the leading cause of death in postmenopausal women, and inflammation is
a key mechanism involved in the pathogenesis of atherosclerosis. High-sensitivity C-reactive protein (hs-CRP) has
been used as a biomarker of inflammation. Considering that CRP gene rs1205 polymorphism has been associated
with hs-CRP circulating levels, we evaluated whether rs1205 genotypes influence the presence of low-grade chronic
inflammation, acting as a marker of cardiovascular risk.
Methods: We performed a cross-sectional study with biobanked blood samples from 327 postmenopausal women
with no evidence of clinical disease. Genotyping for rs1205 C > T SNP of the CRP gene was done by real-time
polymerase chain reaction with allelic discrimination assays.
Results: Mean age was 55.6 ± 5.6 years. Mean body mass index (BMI) was 27.3 ± 4.7. Participants were divided
according to hs-CRP levels: ≥3 mg/l (low-grade chronic inflammation) or < 3 mg/l. The frequency of allele C at
rs1205 was 74.2% in the hs-CRP ≥ 3 mg/l group vs. 59% in the hs-CRP < 3mg/l. In a multivariable model, higher
prevalence of hs-CRP ≥ 3 mg/l was associated with CC genotype (PR 1.53; 95%CI 1.07–2.18; p = 0.018) and waist
circumference ≥ 88 cm (PR 2.45; 95%CI 1.66–3.60; p < 0.001).
Conclusions: CRP rs1205 CC homozygotes may be at higher risk of a low-grade chronic inflammatory status
compared to individuals carrying the T allele.
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Introduction
Cardiovascular disease (CVD) is the leading cause of death
in postmenopausal women. Some evidence suggests that
CVD risk is increased in this population, perhaps as a result
of declining ovarian estrogen secretion, aging, or both [1–3].
Menopause and ageing may also be associated with an un-
favorable phenotype linked to changes in hormones such as
estradiol, sex hormone binding globulin (SHBG), and
follicle-stimulating hormone (FSH), as well as changes in car-
diometabolic profile – including increases in blood pressure,
triglycerides, and low-density lipoprotein cholesterol (LDL-
c), and reduction in high-density lipoprotein cholesterol
(HDL-c) [4–6]. Atherosclerosis, which underlies the occur-
rence of cardiovascular events, develops over decades, and
low-grade chronic inflammation is a key mechanism in its
initiation and progression [7]. Central adiposity, a marker of
visceral adipose tissue, often increases in women during the
menopause transition and post-menopause [8, 9]; emerging
evidence suggests that inflammatory adipokines are released
by this visceral fat depot, possibly contributing to increased
cardiometabolic risk [10, 11].
C-reactive protein is a non-specific, acute phase react-
ant produced by the liver in response to pro-
inflammatory stimuli. This protein is clinically used as a
biomarker of inflammation, and changes in C-reactive
protein levels may be associated with a variety of dis-
eases [12, 13]. The development of high sensitivity la-
boratory assays for C-reactive protein (hs-CRP) has
become an important tool to explore the role of this
reactant as a predictor of cardiovascular events [14, 15].
hs-CRP assays exhibit good stability and reproducibility,
as well as good sensitivity, with a low detection limit
[16]. Many prospective studies have reported a positive
association between hs-CRP levels and CVD, which
seems to imply that the increase in hs-CRP levels reflects
a gradual increase in cardiovascular risk [17–19].
Circulating hs-CRP levels have also been linked to
genetic factors [20]. The heritability of C-reactive pro-
tein secretion has been estimated at 25 to 56% [21–23],
suggesting that genetic variation is an important deter-
minant of C-reactive protein levels. Several genes have
been associated with C-reactive protein secretion, espe-
cially the CRP gene [24, 25]. The CRP gene encoding the
C-reactive protein is located in chromosome region
1q23.2. A single nucleotide polymorphism (SNP), rs1205
C/T, located in the 3′ flanking region of the CRP gene,
has been linked to circulating levels of C-reactive protein
and may influence the expression of this gene [26].
rs1205 has been previously reported as a CRP 3′ UTR
SNP, and its major C allele has been associated with
higher C-reactive protein levels and increased risk of ad-
verse cardiometabolic outcomes [27]. A National Health
and Nutrition Examination Survey (NHANES) analysis
with a population including 41% of postmenopausal
women found an association between serum C-reactive
protein concentration and rs1205 in adult US women
[28]. An epidemiological study of men and women to
determine aging risk factors (AGES-Reykjavik Study)
showed that carriers of allele C of rs1205 captured the
strongest effects on hs-CRP levels [29]..
The evidence that CRP gene SNPs are associated with
CVD risk factors may provide further knowledge regard-
ing disease susceptibility mechanisms. Studies with post-
menopausal women are needed because of the increased
central adiposity-related cardiovascular risk in this group.
Therefore, the aim of the present study was to assess
whether genotypes in the rs1205 SNP of the CRP gene in-
fluence the presence of low-grade chronic inflammation
(hs-CRP ≥3mg/l) considered a novel CV risk factor.
Methods
Study design and participants
This is a cross-sectional study of biobanked samples col-
lected from a population of 327 post-menopausal women
aged between 45 and 65 years without a history of clinical
cardiovascular disease. These women were prospectively
recruited and participated in studies conducted at our re-
search center from 2005 to 2012 [27–29]. Briefly, the first
study [30] was a randomized crossover trial comparing
oral versus non-oral HT. Postmenopausal women consult-
ing for climacteric symptoms at our outpatient clinic at
the Hospital de Clínicas de Porto Alegre, Brazil, were con-
secutively enrolled if they met the following inclusion cri-
teria: not having had a hysterectomy, last menstrual
period between 6months and 3 years before the beginning
of the study plus FSH levels higher than 35 IU/L, not using
any medication known to interfere with hormonal, glu-
cose, or lipoprotein levels in the past 3months, and not
using steroidal or nonsteroidal anti-inflammatory drugs in
the last 15 days. Patients with diabetes, endometrial thick-
ness > 0.5 cm, clinically relevant abnormal mammogram,
history of cancer, thromboembolism, or established car-
diovascular disease were excluded. The present analysis
used data obtained from participants after 3months of
oral or non-oral estradiol treatment.
The second study [31] was cross-sectional in design
(third field visit) and nested in a longitudinal
population-based study of menopausal status that aims
to assess cardiovascular risk among pre-, peri-, and post-
menopausal women through habitual physical activity,
coronary artery calcium, abdominal fat and anthropo-
metric measurements. The detailed study protocol has
been described elsewhere [32]. Only data from postmen-
opausal women were included in the present study.
The third study [33] was also cross-sectional and fo-
cused on dietary protein intake and body composition.
Inclusion criteria in the third study were age between 45
and 65 years, last menstrual period at least 1 year before
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the beginning of the study, FSH levels > 35 IU/L, and no
use of hormone therapy (HT) in the past 3 months.
Women with diabetes or previous diagnosis of heart dis-
ease and current smokers were excluded.
In the three studies, participants were interviewed using
a standardized questionnaire covering demographic char-
acteristics, clinical and gynecologic data, and use of HT
for menopausal complaints. Physical examination did not
reveal any limitations in mobility or cognition, and all par-
ticipants appeared to be healthy. When responding to the
standardized questionnaire, none of the participants re-
ported previous renal or hepatic insufficiency, stroke,
myocardial infarction, or thromboembolic events. In all
three studies, written informed consent was obtained from
all subjects at the time of recruitment for the clinical, la-
boratory, and genetic study components.
The serum samples that had been previously collected
for hormonal assessment were stored in aliquots at −
80 °C. An additional blood sample collected on FTA Elute
cards (GE Healthcare, Buckinghamshire, UK) was avail-
able for DNA extraction and polymorphism genotyping.
Measurements
As previously reported [30, 31, 33], physical examination
was performed with measurement of blood pressure,
weight, height and waist circumference (WC). Body
mass index (BMI) was calculated as weight in kg divided
by the square of height in meters (kg/m2). Metabolic
syndrome was defined by the presence of at least three
of the following: triglycerides ≥150 mg/dl, HDL-c ≤ 50
mg/dl, glucose ≥100 mg/dl, systolic blood pressure ≥ 130
mmHg or diastolic blood pressure ≥ 85 mmHg and waist
circumference ≥ 88 cm [34].
Laboratory analyses
All samples were obtained between 08:00 AM and 10:00
AM. Blood samples were drawn after a 12-h overnight
fast for determination of laboratory analyses. Total chol-
esterol, HDL-c, and triglycerides (TG) were determined
by colorimetric-enzymatic methods (Bayer 1800 Advia
System, Mannheim, Germany), with intra- and inter-
assay coefficients of variation (CV) < 3%. Low-density
lipoprotein cholesterol (LDL-c) was calculated using the
Friedewald formula [35]. Glucose was quantitated by the
hexokinase method (Advia 1800, Mannheim, Germany),
with intra- and inter-assay CV < 3.4%. Serum insulin
levels were measured using ECLIA (Roche Diagnostics,
Mannheim, Germany), with sensitivity of 0.200 μIU/ml
and intra- and inter-assay CVs of 2.0 and 4.3% respect-
ively. The homeostasis model assessment of insulin re-
sistance (HOMA-IR) index was calculated by
multiplying insulin (μIU/ml) by glucose (mmol/l) and
dividing this product by 22.5 [36]. Estradiol was mea-
sured by electrochemiluminescence (Roche Diagnostics,
Mannheim, Germany) with sensitivity of 5.0 pg/ml with
intra- and inter-assay CVs of 5.7 and 6.4%. Individual re-
sults below the limit of sensitivity of the test were con-
sidered as equal to 5.0 pg/mL for statistical analysis.
Interleukin 6 (IL6) was measured in a subsample of 253
subjects, using multiplex immunoassay based on Lumi-
nex® xMAP (Merck KGaA, Darmstadt, Germany) with
sensitivity of 0.2 pg/mL with intra- and inter-assay CVs
of < 10 and < 15% respectively. High-sensitivity CRP [hs-
CRP] was assayed with use of stored specimens, with a
validated nephelometric method (Dade Behring Mar-
burg, Marburg, Germany). Sensitivity was 0.17 mg/l, and
intra-assay and inter-assay CV were 4.4 and 5.7% re-
spectively. For data analysis, individual results below the
limit of sensitivity were considered as equal to 0.17 mg/l.
Values higher than 10 mg/l were excluded from the ana-
lysis due to possible interference of inflammatory pro-
cesses. For the present analysis, participants were
stratified into two groups according to hs-CRP as < 3
mg/l or ≥ 3 mg/l following National Academy of Clinical
Biochemistry Laboratory Medicine Practice Guidelines.
Levels < 1mg/l indicate a low systemic inflammatory
state and lower atherosclerotic risk; 1 to 3 mg/l indicates
moderate vascular risk; and levels > 3 mg/l indicate high
vascular risk when evaluated in the context of other risk
factors [37, 38].
Genotyping
Genomic DNA was extracted from the FTA Elute cards
according to the manufacturer’s protocol (GE Health-
care). Genotyping for rs1205 C > T SNP of the CRP gene
was done by real-time polymerase chain reaction with
allelic discrimination assays (Taqman MGB Probes) fol-
lowing the manufacturer’s instructions (Applied
Biosystems).
Statistical analysis
Results are presented as means ± standard deviation
(SD), medians and interquartile range, or percentages.
Non-Gaussian variables were log-transformed for statis-
tical analysis and reported after being back-transformed
into their original units of measure. Student’s t test was
used for comparisons between groups, and the chi-
square (χ2) test was used to compare categorical vari-
ables. Yate’s correction was used when necessary. Geno-
types were grouped according to the number of subjects
observed in each category. T carriers were grouped for
analysis (heterozygotes plus TT homozygotes vs. CC ho-
mozygotes). The relation of the outcome (CRP levels)
with the variables analyzed was evaluated using preva-
lence ratios (PR) estimated by univariable Poisson re-
gression with robust variance. The hs-CRP < 3mg/l
category was used as reference. Significant variables in
the univariable model were inserted in a multivariable
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model. This method has been recommended as a more ad-
equate alternative than logistic regression for cross-
sectional studies with common binary outcomes [39, 40].
hs-CRP levels were also correlated with all the variables
through Spearman correlation. Linear and multiple regres-
sion were performed to assess the relation between hs-CRP
and the variables analyzed. All analyses were performed
with SPSS for Windows v. 18.0 (SPSS Inc., Chicago, IL,
USA). Data were considered to be significant at p < 0.05.
Results
Table 1 summarizes the clinical and metabolic profile of
the 327 postmenopausal women. The mean age of par-
ticipants was 55.6 ± 5.6 years; 87% were white, and mean
BMI was 27.3 ± 4.7.
The genotype frequencies were in accordance with
Hardy-Weinberg equilibrium. rs1205 genotype frequency
was 39.4% for the CC genotype, 47.4% for the heterozy-
gous CT genotype, and 13.2% for the homozygous TT
genotype. The allele frequencies were 0.63 for C and 0.37
for T, showing a similar pattern to these ones observed in
European and American populations of 1000 genomes
project data (www.internationalgenome.org).
Table 2 presents anthropometric, clinical and meta-
bolic features according to plasma hs-CRP concentra-
tions (< or ≥ 3 mg/l). The hs-CRP < 3mg/l group had
lower waist circumference, BMI, systolic blood pressure,
triglycerides, insulin, and HOMA-IR, and higher HDL-c
than the hs-CRP ≥3 mg/l group (p < 0.05). Metabolic
syndrome was more prevalent (p = 0.040) and IL6 levels
were higher in the hs-CRP ≥3 group (p < 0.001). CRP
categories had similar proportions of self-reported White
women, time since menopause, diastolic blood pressure,
fasting glucose, total cholesterol, and LDL-c.
The frequency of HT-users was slightly, but not sig-
nificantly, higher among participants with hs-CRP < 3
mg/l (p = 0.082) (Table 2).
T carriers were more prevalent in the group with hs-
CRP < 3mg/l (65% vs. 48%, p = 0.008) (Table 2). hs-CRP
plasma levels were significantly higher in CC homozygotes
[2.1 (1.0–3.9)] compared to T carriers [1.5 (0.63–2.6), p =
0.004]. None of the other variables differed between the
rs1205 genotypes (Table 3).
The allelic and genotypic distribution, according to the
hs-CRP categories are presented in Table 4. Allele C at
rs1205 had a frequency of 74.2% in the hs-CRP ≥ 3mg/l
group compared to a frequency for this allele of 59% in
the hs-CRP < 3mg/l group; the same was true for the
genotype (CC 51.7%, CT 44.9% and TT 3.4%).
Prevalence ratios for hs-CRP ≥3mg/l according to geno-
type, metabolic syndrome, age, IL6 level, HOMA-IR, SBP,
HDL-c, triglycerides, insulin, waist circumference and HT
are shown in Table 5 (Model 1). A higher prevalence of
hs-CRP ≥3mg/l was associated with CRP rs1205 CC (PR
1.64; 95%CI 1.15–2.33; p = 0.006), metabolic syndrome
(PR 1.50; 95%CI 1.05–2.15; p = 0.025), age (PR 1.03;
95%CI 1.01–1.06; p = 0.024), IL6 level (PR 1.03; 95%CI
1.01–1.05; p = 0.003), SBP (PR 1.01; 95%CI 1.002–1.02;
p = 0.013), HDL-c (PR 0.98; 95%CI 0.97–0.99; p = 0.024)
and waist circumference ≥ 88 cm (PR 2.46; 95%CI 1.67–
3.64; p < 0.001). Based on the results obtained with uni-
variable models, multivariable models were tested. The
final multivariable model (Model 2 in Table 5) included
having the CC genotype (PR 1.53; 95%CI 1.07–2.18; p =
0.018) and waist circumference ≥ 88 cm (PR 2.45; 95%CI
1.66–3.60; p < 0.001). The remaining variables were not
significant in the multivariable model.
Similar correlations were obtained when hs-CRP was
analyzed as a continuous variable. Age (B = 0.018, 95%CI
0.009–0.028; p < 0.001), waist circumference (B = 0.015;
95%CI 0.011, 0.019; p < 0.001), SBP (B = 0.006; 95%CI
0.003, 0.009; p < 0.001), IL6 level (B = 0.017; 95%CI 0.004,
0.030; p = 0.010) and CC genotype (B = 0.154; 95%CI
0.048, 0.260; p = 0.005) were significantly associated with
hs-CRP in the univariable linear regression. In the multi-
variable regression, age, waist circumference and genotype
remained significantly associated with hs-CRP.
Table 1 Clinical and metabolic features of 327 postmenopausal
women
Variable
Age, years 55.6 ± 5.6
Time since menopause, years 7 (2–10)
Body mass index, kg/m2 27.3 ± 4.7
Waist circumference, cm 87.1 ± 11.4
Systolic blood pressure, mmHg 126.0 ± 18.3
Diastolic blood pressure, mmHg 79.8 ± 11.6
Total cholesterol, mg/dl 209.1 ± 44.6
HDL-c, mg/dl 55.7 ± 12.9
LDL-c, mg/dl 126.3 ± 36.8
Triglycerides, mg/dl 118 (83–163)
Glucose, mg/dl 91 (85–97)
HOMA-IR 1.77 (1.25–2.65)
Insulin, μUI/ml 7.08 (5.4–9.7)
Metabolic syndrome, no (%) 229 (70.5%)
hs-CRP, mg/l 1.8 (0.12–9.9)
IL6, pg/mL 1.13 (0.78–1.77)
Estradiol, pg/ml 35.4 (11.2–70)
HT, n (%) 95 (29.1%)
Data are presented as means (± standard deviation) or as median
(interquartile range), according to Gaussian or non-Gaussian distribution.
Categorical variables (metabolic syndrome and HT) are presented as number
of women (percentage)
HDL-c high-density lipoprotein cholesterol, LDL-c low density lipoprotein
cholesterol, HOMA-IR homeostatic model assessment, hs-CRP high-sensitivity C-
reactive protein, IL6 interleukin 6, HT hormone therapy
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Discussion
In the present study, a higher frequency of the CC genotype
(vs. T carriers) of CRP SNP rs1205 was observed in postmen-
opausal women presenting with CRP levels ≥3mg/l. In fact,
the number of women with hs-CRP levels ≥3mg/l is expected
to be about 50% higher in the CC genotype group as com-
pared to T carriers. While the association of CRP SNP rs1205
with metabolic alterations and cardiovascular risk factors has
been observed in different populations [20, 25, 41–46], to the
best of our knowledge this is the first study to show that asso-
ciation in a specific sample of postmenopausal women with-
out history of clinical disease.
Studies regarding CRP gene polymorphisms and risk
of CVD outcomes are scarce and conflicting. A pro-
spective population-based study that included men and
women aged 55 years and older found no association be-
tween SNP rs1205 or haplotypes and coronary heart
disease [47]. In turn, another study with predominantly
Caucasian men and women observed that the C alleles
of rs1205 and rs18000947 were related to elevated risk
of coronary heart disease [48]. In addition, the Cardio-
vascular Health Study, which enrolled 3941 men and
women aged 65 years or older, showed that the T allele
of rs1205 was associated with lower hs-CRP levels and
decreased CVD mortality [45].
Indeed, haplotype studies are usually more robust in
evidencing the effects of gene polymorphisms on clinical
outcomes. However, rs1205 seems to be the SNP that
captures the strongest effects of the CRP gene on C-
reactive protein levels [23]; the other SNPs that have
been included in the haplotypes are in complete linkage
disequilibrium with rs1205, and do not capture any sig-
nal beyond that detected between rs1205 and hs-CRP
levels [45].
Table 2 Anthropometric, clinical and metabolic characteristics according to hs-CRP levels
hs-CRP
Variable < 3mg/l (n = 238) ≥3 mg/l (n = 89) p-value
Age, years 55.2 ± 5.5 56.7 ± 5.6 0.029a
Time since menopause, years 4 (2–10) 7 (2–12) 0.157a
White participants, % (n) 88.6% (210) 85.1% (74) 0.503b
Waist circumference, cm (n = 292)c
WC < 88 cm 66.35% (140) 35.80% (29) < 0.001b
WC≥ 88 cm 33.65% (71) 64.20% (52)
Body mass index, kg/m2 (n = 287)c
< 24.9 41% (85) 17.50% (14) < 0.001b
25–30 44% (91) 41.25% (33)
> 30 15% (31) 41.25% (33)
SBP, mmHg 125.8 ± 17.4 131.2 ± 19.3 0.021a
DBP, mmHg 79.7 ± 11.1 82.2 ± 11.7 0.084a
Total cholesterol, mg/dl 214.6 ± 41.9 212.2 ± 48.1 0.662a
HDL-c, mg/dl 58.3 ± 14.4 54.4 ± 11.8 0.030a
LDL-c, mg/dl 130.4 ± 36.3 126.5 ± 36.7 0.410a
Triglycerides, mg/dl 115 (76–157) 131 (97–173) 0.018a
Glucose, mg/dl 94.1 ± 24.8 93.4 ± 18.3 0.946a
HOMA-IR 1.6 (1.2–2.4) 2.1 (1.5–3.1) 0.026a
Insulin, μUI/ml 7.4 (5.5–10.1) 9.1 (6.6–13.2) 0.019a
Metabolic syndrome, % (n) 26.2% (62) 38.6% (34) 0.040b
IL6, pg/mL (n = 279)c 1.02 (0.73–1.56) 1.43 (1.08–2.44) < 0.001a
HT, % (n) 32% (76) 21% (19) 0.082b
Oral (n = 54)c 65.7% (44) 52.6% (10) 0.442b
Non-oral (n = 32)c 34.3% (23) 47.4% (9)
T carriers, % (n) 65% (155) 48% (43) 0.008b
Values are expressed as mean (± standard deviation) or median (interquartile range) (25–75%) (aStudent’s t test) or percentage (absolute number) (bχ2 test, with
continuity correction when applicable). cNumber of subjects in sub-sample analyses. P-value of nonparametric variables was obtained after logarithmic
transformation. Percentages of hs-CRP levels to categorical variables are shown in the rows. SBP systolic blood pressure, DBP diastolic blood pressure, HDL-c high-
density lipoprotein cholesterol, LDL-c low-density lipoprotein cholesterol, HOMA-IR homeostatic model assessment. HT hormone therapy, IL6 interleukin 6
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Circulating hs-CRP concentration is well-recognized as
a non-specific marker of low-grade chronic inflammation
[49], and is influenced by age, obesity, sex, smoking status,
use of medications, and genetic factors [50]. Moreover,
prospective studies have shown a strong and consistent
association between elevated hs-CRP concentrations and
various CVD endpoints [51, 52]. Some studies have also
reported an association between ethnicity and higher CRP
levels or subclinical CVD in black women [53, 54]. In the
present study, the proportion of white women was high,
and similar in the two CRP categories. In the South of
Brazil, about 83% of the population are white and descend
from Italian and German immigrants. The remaining 17%
correspond to multiracial and black people (https://sidra.
ibge.gov.br/Tabela/3175#resultado). A similar ethnicity
pattern was observed in our study, and the small number
of non-white postmenopausal women in our sample pre-
cludes any definitive conclusions.
We found that the anthropometric and metabolic pro-
file of women with hs-CRP levels ≥3 mg/l was worse
than that of women with hs-CRP levels < 3 mg/l. Inter-
estingly, the prevalence of metabolic syndrome and IL6,
a more robust marker of low-grade, chronic inflamma-
tion was also higher in the presence of hs-CRP levels ≥3
mg/l. These findings are in accordance with previous
studies [10, 55–57] and suggest an association between
the metabolic syndrome and a chronic inflammatory re-
sponse expressed by increased cytokine secretion.
Table 3 Anthropometric, clinical and metabolic characteristics according to rs1205
rs1205
Variable CC (n = 129) T carriers (n = 198) p-value
Age, years 55.4 ± 5.3 55.7 ± 5.7 0.596a
Time since menopause, years 5 (2–10) 5 (2–12) 0.978a
Waist circumference, cm
WC < 88 cm 39.5% (73) 40.2% (53) 0.994b
WC≥ 88 cm 60.5% (112) 59.8% (79)
Body mass index, kg/m2 (n = 316)c
< 24.9 31.2% (39) 36.1% (69) 0.633b
25–30 44.8% (56) 42.9% (82)
> 30 24.0% (30) 20.9% (40)
SBP, mmHg 125.9 ± 17.8 126.2 ± 18.7 0.902a
DBP, mmHg 80.2 ± 11.5 79.7 ± 11.7 0.714a
Total cholesterol, mg/dl 207.2 ± 46.1 210.5 ± 43.7 0.510a
HDL-c, mg/dl 55.7 ± 12.7 58.8 ± 14.6 0.300a
LDL-c, mg/dl 124.5 ± 40.2 127.5 ± 34.5 0.476a
Triglycerides, mg/dl 140.7 ± 141.8 139.6 ± 118.2 0.938a
Glucose, mg/dl 93.1 ± 18.3 94.2 ± 24.3 0.662a
HOMA-IR 1.7 (1.3–2.3) 1.8 (1.2–2.7) 0.229a
Insulin, μUI/ml 7.3 (5.7–9.8) 8.0 (5.6–11.6) 0.354a
Metabolic syndrome, % (n) 31.8% (41) 28.1% (55) 0.552b
hs-CRP, mg/l 2.1 (1.0–3.9) 1.5 (0.63–2.6) 0.004a
IL6, pg/mL (n = 279)c 1.13 (0.85–1.79) 1.13 (0.76–1.74) 0.285a
HT, % (n) 28.7% (37) 29.3% (58) 0.999b
Values are expressed as (± standard deviation) or median (interquartile range) (25–75%) (aStudent’s t test) or percentage (absolute number) (bχ2 test, with
continuity correction when applicable). cNumber of subjects in sub-sample analyses. P-value of nonparametric variables was obtained after logarithmic
transformation. SBP systolic blood pressure, DBP diastolic blood pressure, HDL-c high-density lipoprotein cholesterol, LDL-c low-density lipoprotein cholesterol,
HOMA-IR homeostatic model assessment, hs-CRP high-sensitivity C-reactive protein, HT hormone therapy, IL6 interleukin 6
Table 4 Allelic and genotypic frequencies according to
categories of hs-CRP
hs-CRP < 3mg/l hs-CRP≥ 3 mg/l p-value
C 281 (59.0%) 132 (74.2%) 0.001
T 195 (41.0%) 46 (25.8%)
CC 83 (34.9%) 46 (51.7%) 0.001
CT 115 (48.3%) 40 (44.9%)
TT 40 (16.8%) 3 (3.4%)
hs-CRP High-sensitivity C-reactive protein
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In addition, our participants with hs-CRP ≥3mg/l had
higher BMI, waist circumference, and HOMA-IR. In this
sense, increased abdominal fatty tissue in postmenopausal
women represents an important source of cytokines – which
stimulate hs-CRP production [9, 10], especially IL6, enhanced
by the interaction with IL1 in hepatocytes. In fact, the hypoxia
caused by adipocyte hypertrophy stimulates the activation of
intracellular nuclear factor-κB (NF-κB), which regulates im-
mune response and induces production of tumor necrosis
factor-α (TNF-α) and interleukins (IL). IL6 is thought to be
the principal cytokine involved in hs-CRP release, and circulat-
ing levels derive mostly from adipose tissue [58]. This mech-
anism might explain the increased levels of hs-CRP and
inflammatory cytokines, such as IL6 and TNF-α, in obese in-
dividuals, and also the positive correlation between these in-
creases and BMI or waist circumference.
CVD risk increases in women at midlife [3], a
period coincident with the menopausal transition [59].
If administered to women with climacteric symptoms
at the first years after menses cessation, HT has been
shown to improve cardiovascular risk factors [60]. We
did not, however, observe any difference in this vari-
able related to hs-CRP categories. This finding seems
to underscore the complexity of HT administration
route and dose – linked on the one hand to the first
pass liver metabolism for oral route estrogen therapy,
and on the other hand to the estrogen-receptor bind-
ing affinity and capacity of different types of estrogen
and doses [61]. Indeed, full-dose oral estrogen therapy
has been associated with an increase in plasma in-
flammatory markers, such as hs-CRP [62]. In turn,
low doses [5] and the non-oral route have not been
associated with changes in hs-CRP levels [30, 63].
One limitation of this study is the relatively small
sample size of 327 participants for analysis of geno-
type/phenotype associations, which does not allow
supplemental evaluations. However, the effect sizes
observed in our sample are similar to those reported
in other populations. Furthermore, consistent results
were obtained with analysis of hs-CRP as either a cat-
egorical or continuous variable. Another limitation is
the use of combined data obtained from a
population-based study but also from convenience
samples included in a clinical trial and an observa-
tional study. Therefore, the present results might not
be generalizable. Conversely, a strength of our study
is the focus on a less well represented ethnic group,
postmenopausal women from southern Brazil.
Table 5 Association analysis of prevalence ratios for clinical and metabolic variables and hs-CRP ≥3 mg/l
Model 1 Model 2
Variable PR (95% CI) p-value PR (95% CI) p-value
rs 1205
CC 1.64 (1.15–2.33) 0.006 1.53 (1.07–2.18) 0.018
T carriers 1 1
MS
Yes 1.50 (1.05–2.15) 0.025 1.19 (0.79–1.80) 0.404
No 1 1
Age, years 1.03 (1.01–1.06) 0.024 1.02 (0.99–1.06) 0.224
IL6, pg/mL 1.03 (1.01–1.05) 0.003 1.02 (0.99–1.04) 0.052
HOMA-IR 1.07 (0.99–1.16) 0.085
SBP, mmHg 1.01 (1.002–1.02) 0.013 1.00 (0.99–1.02) 0.967
HDL-c, mg/dl 0.98 (0.97–0.99) 0.024 1.00 (0.98–1.02) 0.943
Triglycerides, mg/dl 1.001 (1.000–1.002) 0.052
Insulin, μUI/ml 1.01 (0.99–1.03) 0.122
HT
Yes 0.66 (0.42–1.04) 0.072
No 1
WC
< 88 cm 1 1
≥ 88 cm 2.46 (1.67–3 64) < 0.001 2.45 (1.66–3.60) < 0.001
hs-CRP high-sensitivity C-reactive protein, SBP systolic blood pressure, HT hormone therapy, MS metabolic syndrome, WC waist circumference, HOMA-IR
homeostatic model assessment, IL6 interleukin 6, PR prevalence ratio, CI confidence interval
Model 1: PR for each variable
Model 2: multivariable Poisson regression including all the variables that were significant in the univariable analysis. Only the polymorphism and waist
circumference remained significant in the final model
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Conclusion
In conclusion, the present data from a sample of post-
menopausal women with no evidence of clinical disease
suggest that CRP rs1205 CC homozygotes may be at
higher risk of a low-grade chronic inflammatory status
compared to individuals carrying the T allele. Further
longitudinal studies with other menopausal populations
are needed in order to gauge the relationship of SNP
rs1205 with cardiovascular events and the relevance of
ethnic differences for these outcomes.
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